- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00723827
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Temodal (Temozolomide) Post Marketing Surveillance Protocol
The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points that are in question and doubt:
- Incidence of adverse events under actual conditions of use (Serious and Nonserious Adverse Events);
- Adverse Drug Reactions not shown in the directions for use (will be stated as Unexpected Adverse Reaction);
- Adverse Event caused by misuse, abuse, or drug interactions;
- Other information concerned with safety or efficacy.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Participants with newly diagnosed glioblastoma multiforme.
Participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Beschrijving
Inclusion Criteria:
Participants who are prescribed with temozolomide by local labeling:
- participants with newly diagnosed glioblastoma multiforme;
- participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Exclusion Criteria:
- N/A
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
All Participants
Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
|
Administration of temozolomide based on the product labeling.
Andere namen:
Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants Experiencing Adverse Events (AEs)
Tijdsspanne: Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of vaccine, whether or not considered related to the medicinal product.
|
Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Number of Participants Experiencing Unexpected Adverse Drug Reactions (ADRs)
Tijdsspanne: Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
An unexpected ADR was defined as an adverse reaction, whose nature, severity, specificity, or outcome is not consistent with the term or description used in the applicable product information.
|
Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Number of Temozolomide Misuse or Abuse Events
Tijdsspanne: Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Drug abuse was defined as the use of the study drug for a non-therapeutic effect. Misuse was defined as use of the study medication in a way that was not prescribed. |
Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Number of Temozolomide Drug Interactions
Tijdsspanne: Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Drug interaction was defined as a chemical or physiological reaction that can occur when two different drugs are taken together.
|
Complete study duration & 30 days after completion (up to approximately 7.5 months)
|
Efficacy: Number of Participants Experiencing Complete Response (CR), Partial Response (PR), or Stable Disease(SD)
Tijdsspanne: Complete study duration (up to approximately 6.5 months)
|
The response ratings were based on the judgment of the investigator.
|
Complete study duration (up to approximately 6.5 months)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Neoplasmata, glandulair en epitheel
- Glioom
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Glioblastoom
- Astrocytoom
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Antineoplastische middelen, alkylering
- Alkyleringsmiddelen
- Temozolomide
Andere studie-ID-nummers
- P05557
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Glioom
-
The University of Texas Health Science Center at...VoltooidHOOGGRAAD GLIOMAVerenigde Staten
-
National Institute of Neurological Disorders and...VoltooidPrimaire hersentumor | Stralingsnecrose | Glioma Tumor HerhalingVerenigde Staten